List of Baqsimi drug patents
Baqsimi is owned by Eli Lilly And Co.
Baqsimi contains Glucagon.
Baqsimi has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Baqsimi are:
- US6938798
Baqsimi was authorised for market use on 24 July, 2019.
Baqsimi is available in powder;nasal dosage forms.
Baqsimi can be used as treatment of severe hypoglycemia in patients with diabetes.
The generics of Baqsimi are possible to be released after 23 September, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6938798 | ELI LILLY AND CO | Fluid or powdery product dispensing device |
Jan, 2022
(1 year, 4 months ago) | |
| US10213487 | ELI LILLY AND CO | Nasal powder formulation for treatment of hypoglycemia |
Feb, 2036
(12 years from now) | |
| US10894133 | ELI LILLY AND CO | Device for dispensing a fluid product |
Jan, 2038
(14 years from now) | |
| US10765602 | ELI LILLY AND CO | Medication delivery systems and methods |
Sep, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jul 24, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 24 July, 2019
Treatment: Treatment of severe hypoglycemia in patients with diabetes
Dosage: POWDER;NASAL
BAQSIMI family patents
8
United States
7
European Union
6
Japan
4
China
4
France
3
Morocco
3
Australia
2
Canada
2
South Africa
1
Spain
1
Dominican Republic
1
Philippines
1
Malaysia
1
Moldova, Republic of
1
Denmark
1
RS
1
Poland
1
Germany
1
Brazil
1
Ukraine
1
Singapore
1
EA
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Guatemala
1
Cyprus
1
Peru
1
Chile
1
Israel
1
Portugal
1
El Salvador
1
Mexico
1
Costa Rica
1
Ecuador
1
Colombia
1
Lithuania
1
Saudi Arabia
1
Tunisia
1
Slovenia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic